Displaying drugs 13276 - 13300 of 14511 in total
PLX-PAD
Investigational
AMB-301
AMB-301 is an AAV gene therapy delivering E-selectin. It is under investigation for the treatment of Buerger disease.
Investigational
NX001
Investigational
BZ371A
Investigational
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Anti-CD7 CAR T-cell therapy
Investigational
OTOF-GT
OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.
Investigational
DYNE-251
DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
Investigational
DS-2325a
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
SBT101
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
MTL-CEBPA
MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.
Investigational
Firolimogene autotemcel
Investigational
ION582
Investigational
VO659
VO659 is an antisense oligonucleotide being investigated for the treatment of Huntington's disease.
Investigational
ER2001
Investigational
AK-OTOF
Investigational
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
CT120
CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.
Investigational
BMN-351
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
Displaying drugs 13276 - 13300 of 14511 in total